Listen
RAPAMUNE (sirolimus) - Sporadic lymphangioleiomyomatosis
Opinions on drugs -
Posted on
Nov 21 2024
Reason for request
Reassessment
Summary of opinion
Favourable opinion for maintenance of reimbursement in the “treatment of patients withsporadic lymphangioleiomyomatosis with moderate lung disease or declining lung function”.
Clinical Benefit
| Substantial |
The Committee deems that the clinical benefit of RAPAMUNE (sirolimus) remains substantial in “sporadic lymphangioleiomyomatosis with moderate lung disease or declining lung function”. |
Clinical Added Value
| Comments without ASMR value |
The Committee considers that the data provided by the RAPALAM study do not modify the previous conclusions concerning the clinical added value of RAPAMUNE (sirolimus). |
Documents
English version
Contact Us
Évaluation des médicaments
